• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sorafenib improves survival of -mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party.

作者信息

Bazarbachi Ali, Labopin Myriam, Battipaglia Giorgia, Djabali Azedine, Passweg Jakob, Socié Gerard, Forcade Edouard, Blaise Didier, Chevallier Patrice, Orvain Corentin, Cornelissen Jan J, Arcese William, Chantepie Sylvain, Hashaishi Khowla, El Cheikh Jean, Medinger Michael, Esteve Jordi, Nagler Arnon, Mohty Mohamad

机构信息

Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

Department of Cell Biology, Anatomy and Physiological Sciences, American University of Beirut, Beirut, Lebanon.

出版信息

Haematologica. 2019 Sep;104(9):e398-e401. doi: 10.3324/haematol.2018.211615. Epub 2019 Feb 21.

DOI:10.3324/haematol.2018.211615
PMID:30792203
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6717576/
Abstract
摘要

相似文献

1
Sorafenib improves survival of -mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party.索拉非尼可改善异基因干细胞移植后复发的FLT3突变型急性髓系白血病患者的生存率：欧洲血液与骨髓移植协会急性白血病工作组报告
Haematologica. 2019 Sep;104(9):e398-e401. doi: 10.3324/haematol.2018.211615. Epub 2019 Feb 21.
2
Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.索拉非尼和奥马曲星甲酸盐治疗 Fms 样酪氨酸激酶 3 内部串联重复的急性髓系白血病的安全性和有效性。
Cancer. 2020 Jan 15;126(2):344-353. doi: 10.1002/cncr.32534. Epub 2019 Oct 3.
3
Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.索拉非尼对接受异基因造血干细胞移植的伴有 FLT3-ITD 急性髓系白血病患者结局的影响。
Cancer. 2018 May 1;124(9):1954-1963. doi: 10.1002/cncr.31295. Epub 2018 Mar 6.
4
Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.索拉非尼治疗与异基因造血干细胞移植后复发的 FMS 样酪氨酸激酶 3 内部串联重复急性髓系白血病的改善结局相关。
Biol Blood Marrow Transplant. 2019 Aug;25(8):1674-1681. doi: 10.1016/j.bbmt.2019.04.018. Epub 2019 Apr 19.
5
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN).异基因造血干细胞移植治疗伴有内部串联重复突变的急性髓系白血病后的索拉非尼维持治疗（SORMAIN）。
J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16.
6
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.在首次完全缓解的FLT3-ITD急性髓系白血病患者中进行有或没有索拉非尼维持治疗的造血细胞移植。
Br J Haematol. 2016 Nov;175(3):496-504. doi: 10.1111/bjh.14260. Epub 2016 Jul 19.
7
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.索拉非尼作为 Fms 样酪氨酸激酶 3 突变型急性髓系白血病异基因造血干细胞移植后维持治疗药物的疗效和可行性：更新。
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):506-508. doi: 10.1016/j.clml.2019.04.004. Epub 2019 Apr 18.
8
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.索拉非尼维持治疗在异基因造血细胞移植后的FLT3-ITD急性髓系白血病中似乎安全且能改善临床结局。
Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. doi: 10.1016/j.clml.2014.12.005. Epub 2014 Dec 12.
9
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.索拉非尼联合强化化疗可改善初诊、FLT3 内部串联重复突变阳性急性髓系白血病患者的生存。
Cancer. 2019 Nov 1;125(21):3755-3766. doi: 10.1002/cncr.32387. Epub 2019 Jul 16.
10
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.在异基因造血干细胞移植后复发的FLT3-ITD急性髓系白血病中，索拉非尼的血液学缓解率较高。
Eur J Haematol. 2016 Jun;96(6):629-36. doi: 10.1111/ejh.12647. Epub 2015 Sep 21.

引用本文的文献

1
T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments.T细胞急性淋巴细胞白血病：亚型患病率、临床结局及新兴靶向治疗
Leukemia. 2025 Apr 17. doi: 10.1038/s41375-025-02599-2.
2
Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?慢性淋巴细胞白血病中的肿瘤细胞存活因子与血管生成：二者关联有多紧密？
Cancers (Basel). 2024 Dec 29;17(1):72. doi: 10.3390/cancers17010072.
3
Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors.利用小分子抑制剂加速嵌合抗原受体T细胞（CAR-T）疗法
BioDrugs. 2025 Jan;39(1):33-51. doi: 10.1007/s40259-024-00688-9. Epub 2024 Nov 26.
4
The Immunomodulatory Effect of Different FLT3 Inhibitors on Dendritic Cells.不同FLT3抑制剂对树突状细胞的免疫调节作用。
Cancers (Basel). 2024 Nov 4;16(21):3719. doi: 10.3390/cancers16213719.
5
Sorafenib maintenance after allogeneic stem cell transplantation in patients with FLT3+ AML receiving midostaurin during induction and consolidation: a retrospective analysis.在诱导和巩固治疗期间接受米哚妥林治疗的FLT3+急性髓系白血病患者异基因造血干细胞移植后使用索拉非尼维持治疗：一项回顾性分析
Front Oncol. 2024 Sep 19;14:1441254. doi: 10.3389/fonc.2024.1441254. eCollection 2024.
6
Prognostic insights and immune microenvironment delineation in acute myeloid leukemia by ferroptosis-derived signature.基于铁死亡衍生特征的急性髓系白血病预后见解及免疫微环境描绘
Heliyon. 2024 Mar 15;10(6):e28237. doi: 10.1016/j.heliyon.2024.e28237. eCollection 2024 Mar 30.
7
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.Q-HAM 研究：一项多中心、 upfront 随机化的 II 期临床试验，评估了 quizartinib 联合高剂量阿糖胞苷和米托蒽醌在伴有 FLT3-ITD 的复发/难治性 AML 患者中的疗效。
Trials. 2023 Sep 15;24(1):591. doi: 10.1186/s13063-023-07421-x.
8
Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.异基因造血干细胞移植后急性髓系白血病的移植后维持治疗，包括靶向治疗、免疫治疗和细胞治疗等多种治疗方式的协调。
Int J Hematol. 2023 Jul;118(1):1-17. doi: 10.1007/s12185-023-03614-x. Epub 2023 May 22.
9
Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.疾病负担对接受异基因造血细胞移植的急性髓系白血病患者临床结局的影响：欧洲血液与骨髓移植学会急性白血病工作组的一项研究
Bone Marrow Transplant. 2023 Jul;58(7):784-790. doi: 10.1038/s41409-023-01961-1. Epub 2023 Apr 11.
10
Treatment options for acute myeloid leukemia patients aged <60 years.60岁以下急性髓系白血病患者的治疗选择。
Front Oncol. 2022 Oct 5;12:897220. doi: 10.3389/fonc.2022.897220. eCollection 2022.

本文引用的文献

1
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.索拉非尼通过 FLT3-ITD 突变白血病细胞中白细胞介素 15 的产生促进小鼠和人类中的移植物抗白血病活性。
Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12.
2
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.索拉非尼治疗的FLT3-ITD阳性急性髓系白血病患者在异基因干细胞移植后复发的长期生存情况。
Eur J Cancer. 2017 Nov;86:233-239. doi: 10.1016/j.ejca.2017.09.016. Epub 2017 Oct 18.
3
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.米哚妥林联合化疗治疗伴有FLT3突变的急性髓系白血病
N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
4
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.索拉非尼作为Fms样酪氨酸激酶3突变型急性髓系白血病异基因造血干细胞移植后维持治疗药物的疗效及可行性
Cancer. 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7.
5
Inhibition of FLT3 in AML: a focus on sorafenib.急性髓系白血病中FLT3的抑制：聚焦于索拉非尼。
Bone Marrow Transplant. 2017 Mar;52(3):344-351. doi: 10.1038/bmt.2016.251. Epub 2016 Oct 24.
6
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.在首次完全缓解的FLT3-ITD急性髓系白血病患者中进行有或没有索拉非尼维持治疗的造血细胞移植。
Br J Haematol. 2016 Nov;175(3):496-504. doi: 10.1111/bjh.14260. Epub 2016 Jul 19.
7
Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.异基因移植后具有不同分子基因型和细胞遗传学正常 AML 患者的结局。
Blood. 2015 Oct 22;126(17):2062-9. doi: 10.1182/blood-2015-06-651562. Epub 2015 Sep 8.
8
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.索拉非尼维持治疗在异基因造血细胞移植后的FLT3-ITD急性髓系白血病中似乎安全且能改善临床结局。
Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. doi: 10.1016/j.clml.2014.12.005. Epub 2014 Dec 12.
9
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.异基因造血干细胞移植后使用索拉非尼维持治疗FMS样酪氨酸激酶3内部串联重复急性髓系白血病的I期试验
Biol Blood Marrow Transplant. 2014 Dec;20(12):2042-8. doi: 10.1016/j.bbmt.2014.09.007. Epub 2014 Sep 17.
10
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.阿扎胞苷联合索拉非尼治疗伴有 FLT3 内部串联重复突变的急性髓系白血病的 2 期研究。
Blood. 2013 Jun 6;121(23):4655-62. doi: 10.1182/blood-2013-01-480228. Epub 2013 Apr 23.